CHEK2 1100 delC mutation in Russian ovarian cancer patients

BRCA1 and BRCA2 germ-line mutations occur in a significant number of unselected ovarian cancer (OC) patients, thus making a noticeable contribution to OC morbidity. It is of interest whether CHEK2, which is frequently regarded as a third breast cancer specific gene, is also relevant to ovarian cance...

Full description

Saved in:
Bibliographic Details
Published in:Hereditary cancer in clinical practice Vol. 5; no. 3; pp. 153 - 156
Main Authors: Krylova, Nadezhda Yu, Ponomariova, Daria N, Sherina, Natalia Yu, Ogorodnikova, Natalia Yu, Logvinov, Denis A, Porhanova, Natalia V, Lobeiko, Oksana S, Urmancheyeva, Adel F, Maximov, Sergey Ya, Togo, Alexandr V, Suspitsin, Evgeny N, Imyanitov, Evgeny N
Format: Journal Article
Language:English
Published: Poland BioMed Central Ltd 15-09-2007
BioMed Central
BMC
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BRCA1 and BRCA2 germ-line mutations occur in a significant number of unselected ovarian cancer (OC) patients, thus making a noticeable contribution to OC morbidity. It is of interest whether CHEK2, which is frequently regarded as a third breast cancer specific gene, is also relevant to ovarian cancer pathogenesis. In this report we analyzed the presence of CHEK2 1100 delC founder mutation in 268 randomly recruited OC patients. The mutation was identified in 2 women with OC (0.8%) as compared to 1/448 (0.2%) healthy middle-aged and 0/373 elderly tumour-free women. Taken together this result and the negative findings of two other published reports on an association of CHEK2 with ovarian cancer indicate that there is no justification for intensive ovarian cancer screening in CHEK2 1100 delC carriers.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1897-4287
1731-2302
1897-4287
DOI:10.1186/1897-4287-5-3-153